London, UK: 5 December 2005 Cancer drug developer Antisoma plc (LSE: ASM) today announces that it has raised approximately £6.55 million (approximately US $11 million) before expenses through an oversubscribed placing of new ordinary shares. The shares were placed by ING with new and existing institutional investors in the UK and Continental Europe.
